Sign in Register
Posted On: 6 April 2013 12:00 pm
Updated On: 12 November 2020 02:12 pm

New Endometriosis drug introduced in Qatar

Discuss here!
Start a discussion
A new drug for the treatment of endometriosis was introduced in Qatar on Tuesday during a lecture ‘A Stepwise Approach to Managing Endometriosis Pain’ held at Torch Hotel Doha. The new treatment was announced after completing the formal process of registration and licensing with the Supreme Council of Health (SCH). Until the invention of the new medicine, the only treatment of endometriosis was just the simple pain killers and there was no remedy or permanent solution to the problem. Professor Nicholas A Leyland, Professor and Chair of the Department of Obstetrics and Gynaecology, Michael G DeGroote School of Medicine, Hamilton, Canada and Dr Thomas Bossmar, Director of Gynaecology, Obstetrics and Gynaecology Department, Women’s Hospital – Hamad Medical Corporation, (HMC) Doha, delivered the lectures during the Qatar launch event of the medicine. In his lecture, professor Nicholas said, “Some of the symptoms of endometriosis include pain during periods, pre-menstrual pain, which is more severe than the natural menstrual pain and the pain severity does not necessarily involve the large size of endometriosis, severe acute or abnormal uterine bleeding, and infertility.” He said that there are other symptoms, such as fatigue, menstrual cramps, lower back pain, and diarrhoea or constipation, as well as some other menstruation-associated intestinal disorders. “There are, however, some cases that do not suffer from any symptoms,” he added. Dr Bossmar said: “The new medicine would significantly reduce the severity of pain, associated with the disease. The clinical trials that have been made involving women living with endometriosis for up to 15 months at a low dose, found that the new drug contains the active ingredient, Dienogest and can effectively reduce the pain.” He said that the new drug was as effective in treating the disease as a gonadotropin-releasing hormone analogue. He added that clinical studies have also shown that the new drug has no serious side effects of the decrease in the levels of estrogen in the body, such as low bone mineral density, and other menopausal symptoms. Dr Bassem Abdullah, Country Division Head – Gulf, and spokesperson of Bayer HealthCare Middle East, said, “We are committed to improving the health and well-being of women and their families in general, through researching and developing new treatment options for diseases afflicting women folk.” He added, “Doctors and patients concerned with the disease feel that the introduction of the new endometriosis treatment to global and local markets marks a considerable step forward in treating this chronic, debilitating disease.” Source : Qatar Chronicle